biostudies-literatureUnknown22(1)Manzini PM<h4>Background</h4>The efficacy of early treatment with convalescent plasma in patients with COVID-19 is debated. Nothing is known about the potential effect of other plasma components other than anti-SARS-CoV-2 antibodies.<h4>Methods</h4>To determine whether convalescent or standard plasma would improve outcomes for adults in early phase of Covid19 respiratory impairment we designed this randomized, three-arms, clinical trial (PLACO COVID) blinded on interventional arms that was conducted from June 2020 to August 2021. It was a multicentric trial at 19 Italian hospitals. We enrolled 180 hospitalized adult patients with COVID-19 pneumonia within 5 days from the onset of respiratory distress. Patients were randomly assigned in a 1:1:1 ratio to standard of care (n = 60) or standard of care +BMC infectious diseases879https://www.ebi.ac.uk/biostudies/studies/S-EPMC9682750biostudies-literatureConvalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial.PMC9682750Sini BLLonga LALemut FGrillo MBertone SAguzzi CMilia MGAvolio MRusso ARacca FDi Perri GDe Rosa AMolino PPelazza CLiccardi MMBaffa AApra FChinaglia AHu HScozzari GD'Amato TGhiotto SLiuzzi NLucania GDel Bono VPatti FMazzucco LVitale FPoggio GAPrina MMontagnani LVallino DGurioli LGranero VNavarra MMontagnana MCanepari MBerti PValfre ADe Martino DPomero FTorti PVarese PMagro EOttone PPittaluga FMarmifero MAvdis CMeucci MMattei AMacchi SDanielle FAluffi EPellu VMonge ERuscitto LBirocco NCastenetto EConverso MMaddalena LMagnani SNovelli MTavera SCamerini ORomano DCastiglione ARavera EPiovano FPastorelli MEliantonio FGregoretti MGPLACO COVID Study GroupFranza OBrazzi LScapino BVeglio MGFerro FSalio MRicotti MBuffolo FSemino GManno ERoberti GCiccone GGiachino OPellegrino MCLabanca LNico VScaglione LCrocilla CBalduzzi GGuido GCaula GCornagliotto GDoveri GCosta CBergamo DOngaro DRatti DGianotto GDelios GCanta FSolimine CNucci AMessa EOcello PSacchetti PSegala VPrucca MGuaschino RLeoncino SMeinardi SScuvera ITDDe Micheli AGGianarda MAvonto IGalassi CRaso SZiccardi SGiustetto GNorbiato CAlbera CPinna SMGallo VNapoli FCamisasca GPavan ARizzioli GFrascaroli CArtoni PAlbiani RFormica MDe Rosa FGAldieri CBuono GCavallo RBordiga AMGiancaspero KMitola BBenedetti VPerboni ARusso MLVitali EAiosa GGrandinetti VD'Antico SBaldassano SPagnozzi FCiardiello APasquino PGravante UPagliarino MNaselli SBarzaghi NGirino MBlangetti IRadin EFrancisci TArena FVivenza DMLPollis FAmbrogio LScabini SGardini ITornello AChichino GLutri LGhiazza GCianci MGGhisetti VPecoraro CProta RDaffonchio ABeltramo TSantamaria GMGilestro CFassiola ATucciarone MBalbo RLorenzi MSaccona FBalbo VScaglia CNoe EChiappero CVischia FPerotti LRoncato RMilan MCalosso LLocatelli AManzini PMFreilone RPalladino ALivigni SCaironi PLibanore VBoverio RLupo CGamna FLorenzelli LSpidalieri PMarletto FPCastagno FCalcagno AFiore GStrani GLupia ELa Grotta RfalseConvalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial.<h4>Background</h4>The efficacy of early treatment with convalescent plasma in patients with COVID-19 is debated. Nothing is known about the potential effect of other plasma components other than anti-SARS-CoV-2 antibodies.<h4>Methods</h4>To determine whether convalescent or standard plasma would improve outcomes for adults in early phase of Covid19 respiratory impairment we designed this randomized, three-arms, clinical trial (PLACO COVID) blinded on interventional arms that was conducted from June 2020 to August 2021. It was a multicentric trial at 19 Italian hospitals. We enrolled 180 hospitalized adult patients with COVID-19 pneumonia within 5 days from the onset of respiratory distress. Patients were randomly assigned in a 1:1:1 ratio to standard of care (n = 60) or standard of care +2022-01-01T00:00:00Z2022 Nov2026-05-28T20:54:24.594Z2024-12-03T16:22:03.824ZS-EPMC96827503641898410.1186/s12879-022-07716-5